Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail as well as corporate materials mailed to you.

Recent News:

 

2/8/2010 New Animal Model for Evaluating Antiviral Agents Against the SARS Virus Indicates Potential Effect of Ampligen®, an Experimental Therapeutic
...Independent University Researchers Find Ampligen® “Fully Protective” in Study


2/4/2010 Hemispherx Biopharma Appoints Two Senior Pharma Executives to Key Manufacturing Positions

2/2/2010 Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That The FDA Seattle District Accepts Ampligen® Manufacturing Response

1/28/2010 Stanford University Publishes New Data on Immuno-potential of Hemispherx’s Ampligen®
….May Enhance Bioactivity of Cancer Immunotherapies


1/14/2010 Hemispherx Biopharma provides Grant to IACFS to assist in the Development of Chronic Fatigue Syndrome (CFS) Clinical Guidelines

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Dianne Will
Phone:  518-398-6222
Fax:  518-398-6369
or send an e-mail to:
ir@hemispherx.net